Focusing on the transcriptional regulation of ISGs, recent findings in liver cancer indicate that the epigenetic modifier EZH2 can suppress PD-L1 expression by upregulating the level of H3K27me3 at the promoters of both the CD274 gene (which encodes PD-L1) and the IRF-1 gene. Here, IRF1 is linked to liver cancer.